Assessment of Vitronectin, Soluble Epithelial-Cadherin and TGF-β1 as a Serum Biomarker with Predictive Value for Endometrial and Ovarian Cancers

Background: The objective of this study is to evaluate the predictive value of serum CA-125 changes in the management of patients undergoing neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) in advanced epithelial ovarian carcinoma (EOC).Methods: A retrospective hospital-based study of patients with advanced epithelial ovarian cancers (stage III and IV) was conducted at Department of Obstetrics and Gynecology in Gujarat Cancer and Research Institute, Ahmedabad, for two years. Total 50 patients were treated with NACT followed by surgical cytoreduction and followed up till August 2010. Response to NACT, optimal cytoreduction rate and overall response rate were analyzed.CA 125 levels before (baseline) and after NACT were analyzed.Results: Out of 50, there were 43 patients (86%) with stage III disease and 7 (14%) with stage IV disease. Maximum 37(74%) patients had CA 125 levels >500 on presentation while none of the patients had baseline CA125 levels in the normal range (<35). Range of baseline CA 125 was 164-5394.All patients were given NACT and after NACT, out of 50 patients, 22(44%) patients had CA 125 values within the normal range (<35) while 23(46%) had values between 35 and 100. Thus, statistically significant difference (Z = 6.154, P<0.0001) was found between CA 125 level before and after NACT. Out of 45 patients with CA 125 <100, 35(77.8%) underwent optimal cytoreduction.Conclusions: Baseline (prechemotherapy) serum CA-125 levels are powerful indicators of the presence and extent of spread of disease while CA-125 level particularly <100U/ml after NACT strongly predicts optimal cytoreduction in advanced epithelial ovarian cancers.

Download Full-text

Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer

British Journal of Cancer ◽

10.1038/sj.bjc.6602599 ◽

2005 ◽

Vol 92 (11) ◽

pp. 2018-2023 ◽

Cited By ~ 33

Author(s):

R Kuefer ◽

M D Hofer ◽

C S M Zorn ◽

O Engel ◽

B G Volkmer ◽

...

Keyword(s):

Prostate Cancer ◽

Predictive Value ◽

Serum Biomarker ◽

E Cadherin

Download Full-text

Diagnostic Value of Serum Biomarker Human Epididymis Protein4 in Ovarian Cancers

American Journal of Laboratory Medicine ◽

10.11648/j.ajlm.20200501.13 ◽

2020 ◽

Vol 5 (1) ◽

pp. 18

Author(s):

Rimaz Elhag Gurashi ◽

Moawia Elsadig Hummeida ◽

Faisal Galal Abdelaziz

Keyword(s):

Diagnostic Value ◽

Serum Biomarker ◽

Human Epididymis ◽

Ovarian Cancers

Download Full-text

Predictive Value of Complete Blood Count Inflammatory Parameters for Epithelial Ovarian Cancers in Women During Reproductive Period

Acta Oncologica Turcica ◽

10.5505/aot.2021.30922 ◽

2021 ◽

Vol 54 (2) ◽

pp. 217-223

Author(s):

Hilal Korkmaz ◽

Mustafa Akşar ◽

Halis Doğukan Özkan ◽

Vakkas Korkmaz ◽

Nurettin Boran

Keyword(s):

Predictive Value ◽

Blood Count ◽

Complete Blood Count ◽

Reproductive Period ◽

Inflammatory Parameters ◽

Ovarian Cancers

Download Full-text

Risk of Malignancy Index Has a Poor Sensitivity in Detecting Borderline Epithelal Tumors and Non-Epithelial Ovarian Tumors

Gynecology Obstetrics and Reproductive Medicine ◽

10.21613/gorm.2018.847 ◽

2019 ◽

pp. 1

Author(s):

Yasin Durmus ◽

Mehmet Mutlu Meydanli

Keyword(s):

Predictive Value ◽

Ovarian Tumors ◽

Ca 125 ◽

Histopathological Diagnosis ◽

Adnexal Masses ◽

Epithelial Tumors ◽

Ovarian Cancers ◽

Risk Of Malignancy ◽

Risk Of Malignancy Index ◽

The Difference

Objectives: To evaluate diagnostic accuracy of "Risk Of Malignancy İndex-1" (RMI-1) for postmenopausal adnexal masses.Study Design: Fifty postmenopausal women who had undergone surgery because of adnexal masses were included in this prospective study. RMI-1 scores were calculated through the formula: [RMI= Ultrasound Score x Menopause Score x Serum Ca-125 Level] and noted preoperatively by the same sonographer for each case. "Final histopathological diagnosis" was accepted as gold standard for benign-malignant categorical distribution. Borderline tumors were categorized in malignant tumor group. Results: According to final histopathological results; 20 of the 50 patients had malignant adnexal masses. Twelve of them had invasive epithelial tumors. The remaining 8 patients had borderline epithelial tumors or non-epithelial ovarian cancers. When the RMI score ≥200 was accepted as a positive test result compatible with the literature; we calculated the sensitivity: 75%, specificity: 93%, positive predictive value: 88%, negative predictive value: 85% predicting malignant adnexal masses. All of the 12 patients with invasive epithelial tumors had RMI-1 scores higher than 200. Nevertheless, only 3 of the 8 patients with borderline epithelial tumors or non-epithelial ovarian cancers had RMI-1 scores higher than 200. We have found out that invasive epithelial tumors had higher USG Scores, Ca-125 Levels and RMI Scores when compared to borderline epithelial tumors and non-epithelial ovarian cancers and the difference was statistically significant. Conclusions: RMI-1 is a valuable and applicable method in the initial evaluation of postmenopausal patients with adnexal masses. İt has a high diagnostic performance in detecting invasive epithelial ovarian cancers, but it has a poor sensitivity in detecting borderline ovarian tumors and non-epithelial ovarian cancers.

Download Full-text

Is it possible to use the serum levels of alpha 1-antitrypsin as a serum biomarker to distinguish endometriosis and endometriosis-associated epithelial ovarian cancers?

Journal of the Chinese Medical Association ◽

10.1097/jcma.0000000000000644 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Yiu-Tai Li ◽

Wen-Ling Lee ◽

Peng-Hui Wang

Keyword(s):

Serum Levels ◽

Serum Biomarker ◽

Ovarian Cancers ◽

Alpha 1 Antitrypsin

Download Full-text

Smad4 is predictive for response in neoadjuvant treated esophageal squamous cell carcinoma

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.4591 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 4591-4591

Author(s):

B. L. Brücher ◽

F. Pühringer-Oppermann ◽

M. Sarbia

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Predictive Value ◽

Roc Analysis ◽

Locally Advanced ◽

Rna Extraction ◽

Histopathological Response ◽

Tgf Β1

4591 Background: The evaluation of the prevalence of TGF-β1-pathway gene expressions (TGF-β1, Smad7 and Smad4) and its predictive value for histopathological response in patients with esophageal squamous cell carcinoma and neoadjuvant radiochemotherapy. Methods: RNA was prepared from pretherapeutic taken formalin-fixed and paraffin-embedded biopsies of 98 patients with histological proven locally advanced ESCC (cT3, cN0/+, cM0), who underwent preoperative combined simultaneous RTx/CTx with consecutive esophagectomy. All tumor biopsies underwent tumor-cell-microdissection, RNA-extraction and real-time TaqMan reverse transcriptase- polymerase chain reaction. RT-PCR-measurements were made by doublet measuring. Quantitative mRNA expression of TGFβ1 and its downstream effectors Smad4 and Smad7 was correlated with histopathological response by the percentage of residual tumor cells. Analysis was performed by dichotomized calculation and for determination of a cut-off by ROC-analysis. Results: Dichotomized analysis revealed the following median values: Smad4=0.098± 0.7 (CI: 0.024–0.396), Smad7=1.9250±1.7 (CI: 0.4–16.1) and TGFβ1=6.427±4.86 (CI: 0- 25.7). Cross-tabs-analysis for histopathological response disclosed the following correlations: TGFβ1 (p=0.671), Smad7 (p=0.672) and Smad4 (p=0.038). ROC-analysis revealed a Smad4-cut-off of 0.0635 by an area-under-curve of 6280 (p=0.038). Consecutive re-cross-tabs-analysis of histopathological response revealed a sensitivity of 80% (p=0.013). The pretherapeutic predictive value of Smad4 was 73%. Medians in survival was not reached during follow-up, whether TGFβ1 (p=0.519), Smad7 (p=0.5728) nor Smad4 (p=0.552). Histopathological responders showed a significant better survival compared to nonresponders (p<0.0001). Conclusions: High levels of Smad4 gene expression are significantly correlated with histopathological response. ROC-Analysis identified a cut-off of Smad4 with a sensitivity of 80% and a predictive value of 73%. No significant financial relationships to disclose.

Download Full-text

Proteomics of the ascitic fluid for the differentiation of advanced ovarian cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e15510 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e15510-e15510

Author(s):

Gururao Hariprasad ◽

Roopa Hariprasad ◽

Lalit Kumar ◽

Amit Kaushik ◽

Alagiri Srinivasan

Keyword(s):

Ovarian Cancer ◽

Ascitic Fluid ◽

Predictive Value ◽

Advanced Ovarian Cancer ◽

The Body ◽

Apolipoprotein A1 ◽

Differentially Expressed ◽

Ovarian Cancers ◽

Potential Biomarker ◽

Clinical Scenarios

e15510 Background: Ovarian cancers are classified as primary, if it arises in the ovary and secondary or metastatic, if the origin is from other parts of the body. The clinical manifestations of these cancers in the advanced stage are very similar making it difficult to distinguish clinically, hiostopathologically and radiologicaly. The therapeutics and management of the primary and secondary malignancies are completely different. While, the advanced primary malignancies are treated by cytoreduction followed by chemotherapy, the metastatic tumors are treated mainly with palliative chemotherapy. The prognosis is better for primary than secondary ovarian cancer making their diagnosis very crucial for patient care. Methods: 1D and 2D-gel based proteomic approaches were used to study the differentially expressed proteins in the ascitic fluid of patients (10 primary and 4 secondary) with advanced ovarian cancer. The relative ratios of the protein expression were estimated by densitometric analysis. The bands/spots with more than three fold difference were subjected to in-gel trypsin digestion and identified by mass spectrometric analysis. The differential expression of one of the proteins was further validated by western blot experiments and ELISA. Results: Programmed Cell Death 1-Ligand 2 and apolipoprotein A1 were seen to be up regulated in the advanced primary ovarian cancer while apolipoprotein A4, and chain L, humanized version of the anti-human fas antibody Hfe7a were seen to be up regulated in the metastatic variant. Validation for the expression of apolipoprotein A1 shows that a 61.8ng/ml cut off is ideal to differentiate the primary and secondary advanced ovarian cancers. The assay has 100% sensitivity, 75% specificity, positive predictive value of 90.9%, negative predictive value of 100%, accuracy of 92.85% and a pre-test odds positive of 2.5. Conclusions: Proteomics of ascitic fluid is useful for the differentiation of advanced ovarian cancers. There are proteins which are differentially expressed in the ascitic fluid of patients with primary and secondary ovarian cancer. Apolipoprotein A1 is a potential biomarker that can be used to differentiate the closely mimicking clinical scenarios of advanced ovarian cancer.

Download Full-text

CYFRA 21-1 as a novel diagnostic serum biomarker in pancreatic cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.3_suppl.191 ◽

2014 ◽

Vol 32 (3_suppl) ◽

pp. 191-191

Author(s):

Jung Hoon Kim ◽

Joon Cheol Song ◽

Jung Hyun Kwon ◽

Dae Kyun Kim ◽

Dong Wook Jekarl ◽

...

Keyword(s):

Pancreatic Cancer ◽

Serum Concentration ◽

Positive Predictive Value ◽

Negative Predictive Value ◽

Predictive Value ◽

Advanced Disease ◽

Serum Biomarker ◽

Control Group ◽

Intermediate Filament Proteins ◽

Sensitivity Specificity

191 Background: CYFRA 21-1 is a fragment of cytokeratin 19, a structure protein and part of intermediate filament proteins contributing to stability of epithelial cells. Serum concentration of CYFRA 21-1 is known to be elevated in many types of epithelial malignancies, and especially it has a prognostic and predictive value in patients with non-small cell lung cancer. We assessed serum CYFRA 21-1 and studied its clinical significance in patients with pancreatic cancer. Methods: The sera from 52 patients diagnosed with pancreatic cancer was collected between May 2012 and August 2013 at Incheon St. Mary’s hospital, Catholic University of Korea, School of Medicine and was measured for CYFRA 21-1 and CA 19-9. 48 patients had an advanced disease at presentation, 2 patients had a locally advanced disease, and 2 patients presented with a local disease. Control blood samples were obtained from 31 healthy individuals and 48 patients with nonmalignant hepatic or pancreatobiliary disease. We measured CYFRA 21-1 using two-step sandwich, chemiluminescent microparticle immunoassay, Architect i2000SR (Abbott Laboratories, Ltd., Il, USA). Results: Serum concentration of CYFRA 21-1 was significantly elevated in patients with pancreatic cancer compared with control group. (p=.000) CYFRA 21-1 ( >1.96 ng/ml as determined by the ROC curve) had a sensitivity, specificity, positive predictive value, and negative predictive value of 86.5%, 79.7%, 73.8%, 90% for the diagnosis of pancreatic cancer. Additionally, CA 19-9 ( >35 U/ml determined by our institute’s criteria) had a sensitivity, specificity, positive predictive value, and negative predictive value of 67.3%, 89.9%, 69.1%, 81.6%. The area under curve for CYFRA 21-1 and CA 19-9 was 86.3% and 81.5%, respectively. Conclusions: CYFRA 21-1 has a potential to become a novel serum biomarker for the diagnosis of pancreatic cancer. Serum concentration of CYFRA 21-1 in combination with CA 19-9 can be useful in clinical practice to diagnose pancreatic cancer.

Download Full-text